|
|
|
|
| LEADER |
00000cam a2200000Ii 4500 |
| 001 |
EBSCO_ocn958279618 |
| 003 |
OCoLC |
| 005 |
20231017213018.0 |
| 006 |
m o d |
| 007 |
cr cnu|||unuuu |
| 008 |
160912s2016 nyu ob 001 0 eng d |
| 040 |
|
|
|a N$T
|b eng
|e rda
|e pn
|c N$T
|d N$T
|d EBLCP
|d SNK
|d DKU
|d AUW
|d IGB
|d D6H
|d OCLCF
|d VTS
|d AGLDB
|d AU@
|d OCLCO
|d G3B
|d OCLCA
|d S8J
|d S9I
|d STF
|d OCLCQ
|d OCLCO
|d OCLCQ
|d OCLCO
|
| 020 |
|
|
|a 9781634854795
|q (electronic bk.)
|
| 020 |
|
|
|a 1634854799
|q (electronic bk.)
|
| 020 |
|
|
|z 9781634854597
|
| 035 |
|
|
|a (OCoLC)958279618
|
| 050 |
|
4 |
|a RC869
|
| 060 |
|
4 |
|a WI 575
|
| 072 |
|
7 |
|a MED
|x 010000
|2 bisacsh
|
| 072 |
|
7 |
|a MED
|x 022000
|2 bisacsh
|
| 072 |
|
7 |
|a MED
|x 045000
|2 bisacsh
|
| 082 |
0 |
4 |
|a 616.13
|2 23
|
| 049 |
|
|
|a UAMI
|
| 245 |
0 |
0 |
|a Ascites :
|b aetiology, symptoms and treatment /
|c Eleanor Figueroa, editor.
|
| 264 |
|
1 |
|a New York :
|b Nova Biomedical,
|c 2016.
|
| 300 |
|
|
|a 1 online resource.
|
| 336 |
|
|
|a text
|b txt
|2 rdacontent
|
| 337 |
|
|
|a computer
|b c
|2 rdamedia
|
| 338 |
|
|
|a online resource
|b cr
|2 rdacarrier
|
| 347 |
|
|
|a data file
|2 rda
|
| 490 |
1 |
|
|a New developments in medical research
|
| 504 |
|
|
|a Includes bibliographical references and index.
|
| 588 |
0 |
|
|a Online resource, title from PDF title page (EBSCO), viewed September 21, 2016.
|
| 505 |
0 |
|
|a ASCITES: AETIOLOGY, SYMPTOMS AND TREATMENT; ASCITES: AETIOLOGY, SYMPTOMS AND TREATMENT; Library of Congress Cataloging-in-Publication Data; CONTENTS; PREFACE; Chapter 1: ASCITES IN HUMAN LIVER CIRRHOSIS; ABSTRACT; LIVER CIRRHOSIS; CLINICAL EVOLUTION OF LIVER CIRRHOSIS; Ascites; BACTERIAL TRANSLOCATION; SPONTANEOUS BACTERIAL PERITONITIS; INTESTINAL MICROBIOTA ALTERATIONS IN CIRRHOTIC PATIENTS; PERITONEAL HOST DEFENSE MECHANISMSIN HEALTHY INDIVIDUALS; ALTERATIONS IN PERITONEAL IMMUNERESPONSE IN CIRRHOSIS; Alterations at Cellular Level; Alterations at Molecular Level
|
| 505 |
8 |
|
|a INCREASED INTESTINAL PERMEABILITY LEADSTO EXHAUSTION OF THE IMMUNE SYSTEMPITFALLS AND LIMITATIONS OF STUDIESPERFORMED IN LIVER CIRRHOSIS ASCITES; Experimental Animal Models; Etiology; Sample Size and Clinical Stage Variability among Patients; Healthy Control Reference; CONCLUSION; REFERENCES; Chapter 2: DIFFERENCES IN THE INFLAMMATORY STATUS DERIVED ON AETIOLOGY IN HUMAN LIVER CIRRHOSIS; ABSTRACT; INTRODUCTION; NATURAL HISTORY OF LIVER CIRRHOSIS; AETIOLOGY OF CIRRHOSIS; THE DEVELOPMENT OF ASCITES INDUCEDBY LIVER CIRRHOSIS; BACTERIAL TRANSLOCATION IN LIVER CIRRHOSIS
|
| 505 |
8 |
|
|a INFLAMMATORY STATUS IN ASCITESOF DECOMPENSATED LIVER CIRRHOSISSTUDIES COMPARING HCV- VSALCOHOL-INDUCED CIRRHOSIS; DIFFERENCES BETWEEN THE PERITONEAL INFLAMMATORY STATUS IN CIRRHOTIC ASCITES INDUCED BY ALCOHOL AND HCV INFECTION; CONCLUSION; REFERENCES; Chapter 3: MINIMALLY INVASIVE MANAGEMENT OF REFRACTORY MALIGNANT ASCITES; ABSTRACT; 1. INTRODUCTION; 2. CAUSES OF REFRACTORY MALIGNANT ASCITES; A. Mechanisms of Production; 3. MINIMALLY INVASIVE MANAGEMENT OF REFRACTORYMALIGNANT ASCITES; A. Historical Background; B. Indications; C. Contraindications; D. Devices; I. Peritoneal Tunneled Catheters
|
| 505 |
8 |
|
|a PleurX Drainage System (Figure 1)Aspira® Drainage System (Figure 2); II. Peritoneal Ports; E. Technique; I. Peritoneal Tunneled Catheters; Pre-Procedure Preparation; Intra-Procedure Preparation; Tunneled Catheter Placement Using Ultrasound and FluoroscopicGuidance; Drainage; II. Peritoneal Ports; Pre-Procedure Preparation; Intra-Procedure Preparation; Peritoneal Port Placement Using Ultrasound and FluoroscopicGuidance; Drainage; F. Potential Complications; 4. OUTCOMES; CONCLUSION; REFERENCES; Chapter 4: A LOOK AT THE MANAGEMENT AND USAGE OF MALIGNANT ASCITES IN OVARIAN CANCER; ABSTRACT
|
| 505 |
8 |
|
|a INTRODUCTION1. ASCITES; 1.1. Definition of Ascites; 1.2. Malignant Ascites in Ovarian Cancer; 1.3. Management of Malignant Ascites in Ovarian Cancer; 1.3.1. Non-Molecular Therapy; 1.3.1.1. Paracentesis; 1.3.1.2. Catheter Drainage; 1.3.1.3. Diuretic Therapy; 1.3.1.4. Concentrated Ascites Reinfuision Therapy (CART); 1.3.2. Molecular Therapy; 1.3.2.1. Catumaxomab; 1.3.2.2. Anti-Angiogenesis Treatment; 2. ROLE OF MALIGNANT ASCITES IN OVARIAN CANCER; 2.1. Dissemination; 2.1.1. Routes of Dissemination; 2.1.2. Ascites as a Carrier; 2.2. Angiogenesis; 2.2.1. General Information
|
| 590 |
|
|
|a eBooks on EBSCOhost
|b EBSCO eBook Subscription Academic Collection - Worldwide
|
| 650 |
|
0 |
|a Ascites
|x Treatment.
|
| 650 |
|
0 |
|a Diseases
|x Causes and theories of causation.
|
| 650 |
|
2 |
|a Ascites
|x therapy
|
| 650 |
|
6 |
|a Ascites
|x Traitement.
|
| 650 |
|
6 |
|a Étiologie.
|
| 650 |
|
7 |
|a MEDICAL
|x Cardiology.
|2 bisacsh
|
| 650 |
|
7 |
|a MEDICAL / Diseases
|2 bisacsh
|
| 650 |
|
7 |
|a MEDICAL / Internal Medicine
|2 bisacsh
|
| 650 |
|
7 |
|a Diseases
|x Causes and theories of causation
|2 fast
|
| 700 |
1 |
|
|a Figueroa, Eleanor,
|e editor.
|
| 830 |
|
0 |
|a New developments in medical research.
|
| 856 |
4 |
0 |
|u https://ebsco.uam.elogim.com/login.aspx?direct=true&scope=site&db=nlebk&AN=1350584
|z Texto completo
|
| 938 |
|
|
|a ProQuest Ebook Central
|b EBLB
|n EBL4691217
|
| 938 |
|
|
|a EBSCOhost
|b EBSC
|n 1350584
|
| 994 |
|
|
|a 92
|b IZTAP
|
